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Dear Editor,
In a very interesting paper, Haridas et al. have shown that
patients with intraoperative floppy iris syndrome (IFIS) re-
ceiving tamsulosin or doxazosin differ in terms of morbidity
rates [1].
Among 2,785 cataract operations performed in 2,028 pa-
tients, the authors identified 52 (1.9 %) cases treated with
tamsulosin and 109 (3.9 %) cases in which doxazosin was
administered. They compared morbidity rates between these
two groups.
In our opinion, however, some aspects of this study need to
be discussed. In their retrospective analysis, the authors found
at least one IFIS feature in 17 out of 106 eyes (16 %) from the
doxazosin group and in 25 out of 52 eyes (48 %) from the
tamsulosin group. Alpha-1 antagonists, used in the symptom-
atic treatment of benign prostatic hyperplasia, may increase
the surgical difficulties and risk of iris damage, corneal edema,
posterior or anterior capsule rupture, and postoperative in-
crease in intraocular pressure [2–4]. Nevertheless, analysis
of data expressed as percentages can be misleading and pro-
vide false information on the prevalence of IFIS and expected
intraoperative morbidity rate.
In Table 1 of their paper, Haridas et al. presented data on the
size of the pupil and status of the iris in the tamsulosin and
doxazosin groups [1]. However, the prevalence of various
abnormalities (large or small pupil, iris prolapse, etc.) was
expressed as a percentage of IFIS cases in a given group, i.e.
per 25 and 17 eyes in tamsulosin and doxazosin group, re-
spectively. In our opinion, however, the prevalence should be
rather expressed per the whole group administered a given
agent, i.e. per 52 and 106 eyes of patients treated with
tamsulosin and doxazosin, respectively. Only in this way can
we estimate the potential risk of intraoperative complications
in patients treated withα-1 antagonists. Furthermore, it should
be noted that expressing seven cases of intraoperative com-
plications in the tamsulosin group as 13.5 % (7 out of 52 eyes)
suggests that such morbidity can be expected in patients
subjected to cataract surgeries. This is not true, as intraopera-
tive complications documented in the tamsulosin IFIS group
(iris damage – 5 cases, anterior capsule rupture – 1 case,
corneal edema – 1 case) corresponded to only 0.3 % of all
2,785 operated eyes, the average rate of cataract complications
in non-IFIS patients. Takmaz analyzed a group of 858 oper-
ated eyes and identified intraoperative complications in 6 eyes
of patients who were treated with tamsulosin [8]. However, he
emphasized the lack of significant differences in the morbidity
rates of tamsulosin-treated patients with and without IFIS (p=
0.245). According to Haridas et al., patients treated with
tamsulosin differed significantly from the controls in terms
of the morbidity rates (13.5 %, i.e. 7 out of 52 eyes vs. 3.3 %,
i.e. 5 out of 150 eyes; p=0.014) [1]. However, we postulate
that statistical analyses are not justified in the case of such a
large disproportion in group size. Furthermore, this analysis
was not adjusted for surgeon’s experience and other intraop-
erative factors.
The exact data on the type and prevalence of intraoperative
complications is missing in available literature. (Table 1)
Chang et al. spoke to the intraoperative use of retractors in
five cases but did not provide any data on the percentage of
postoperative iris damage in patients with IFIS [2]. In turn, the
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report by Oshika et al. not only lacks any data on postopera-
tive morbidity rates but does not provide any information
about intraoperative strategies of performing cataract
phacoemulsification in patients with IFIS [6].
Concluding: Although the use of α-1 antagonists, especial-
ly tamsulosin, can constitute a potential risk of intraoperative
complications in cataract surgery, such complications occur
sporadically, and therefore, the morbidity rates should be
presented in a uniform manner in order to avoid their inadver-
tent overestimation.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and the
source are credited.
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Complication rate (% of all cases)






AC rupture – 1 case (0,04 %); 5 eyes
with iris damage (0,2 %); 1 eye
corneal oedema







PC rupture & vitreous loss- 2
cases (0,4 %)







AC rupture - 1 case (0,1 %);




















PC rupture - 1 case
(0,08 %); 3 eyes with iris damage;
zonular dehiscence-1 case; retained
lens fragments – 1 case; CME –
2 cases






PC rupture - 1 case (0,1 %); 5 eyes
with iris damage (0,6 %)
Nguyen et al [9]. (2007) Unknown Unknown/606 cases Unknown/363 cases Difficult to assess, PC rupture – 7 % of
unknown number of cases








PC rupture - 1 case
(0,2 %)
IFIS intraoperative floppy iris syndrome, AC anterior capsule, PC posterior capsule, CME cystoids macular oedema
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